Will Indutrade AB’s SEK 1.1 Billion Acquisition Wave Ignite the Next Growth Wave?

Indutrade AB reported its third-quarter results for 2025, highlighting several key aspects of its recent performance. The company’s order intake saw improvement compared to the previous year, with notable growth in four of its five business areas and strong continued demand from the medical technology and pharmaceuticals sectors. However, net sales experienced a decline of 2% overall, with a 1% drop in organic sales, which was primarily attributed to weaker sales in the Life Science business area due to tough comparatives with significant sales to Novo Nordisk in the same period last year.